فهرست نشریات علمی دسترسی آزاد ایران

Background: Intrathecal opioids have demonstrated efficacy in pain management during and after surgery, necessitating further exploration across various surgical procedures. This study examines the use of higher doses of intrathecal synthetic opioids (Sufentanil) for pain control in gastrointestinal cancer surgeries, highlighting the need for additional research to establish conclusive outcomes. Methods: A single-center clinical trial with a control group was conducted, involving adult non-addicted individuals eligible for gastrointestinal cancer surgeries. The intervention group (n=25) received intrathecal Sufentanil (0.2 mcg/kg) before anesthesia induction, while the control group (n=25) received intravenous Sufentanil (0.3 mcg/kg) at induction. The variables between the two groups were compared using chi-square tests, independent t-tests, and exact tests. Results: The average age in the intrathecal group was 55.1 years ± 9.3, and in the intravenous administration group was 54.2 years ± 13.2, showing no significant difference (p=0.4). A higher proportion of patients in the intrathecal group required three analgesic doses (52%) compared to the IV group, where 44% needed four doses during surgery, with no significant variance observed between groups (p=0.3). Postoperative pain scores were lower in the intrathecal group than in the intravenous administration group (0.8 ± 1.7 vs 0.66 ± 5.12, p<0.001). Conclusion: Based on our study findings, Intrathecal Sufentanil at a dose of 0.2 mcg/kg reduces postoperative pain by one-third compared to IV administration in gastrointestinal cancer surgeries.